STAT+: 3 CRISPR advances to watch in 2024
Approval of the first CRISPR-based medicine paves the way for in vivo therapies, as well as treatments using next-gen genome editors.
Life in the CRISPR lane tends to move at lightning speed. This year saw the first-ever approval of a medicine based on the gene editing technology, barely more than a decade after publication of its first demonstration by Nobel laureates Jennifer Doudna and Emmanuelle Charpentier.
The landmark decision paves the way for in vivo therapies, which edit cells inside the body, to reach patients, as well as treatments based on more efficient genome editors with fancier DNA-altering tricks up their sleeves.
Here are three CRISPR developments we’re watching in 2024:
What's Your Reaction?
